Life Science Leader Chief Editor Blog Header image Life Science Leader Chief Editor Blog Header image

What Does The Successful Killing Of The Pfizer Allergan Deal Mean?
What Does The Successful Killing Of The Pfizer Allergan Deal Mean? When I wrote the opinion piece on the U.S. government’s successful killing of the planned Pfizer Allergan merger, it was on the heels of a March Editor’s Note on the current state of U.S. corporate taxes. There are those who argue that U.S. companies aren’t seeking to invert due to high U.S. tax rates. And while we can dispute the rationale behind why companies have been seeking to relocate outside the United States, what...  Continue Reading...
Evolving The Biopharma R&D Model — Improbable Players Are Changing The Game
Evolving The Biopharma R&D Model — Improbable Players Are Changing The Game At a recent conference* I overheard an executive comment that the clinical trial space remains one of the biggest bottlenecks to successful drug development. Sure, companies are developing much more sophisticated and targeted therapies. However, one of the problems this more individualized drug development creates is a slowdown in clinical trial recruitment. While new technologies are creating an enormous amount of clinical evidence, for the...  Continue Reading...
Is U.S. Government Tactical Switch From Too Big To Fail To Too Big To Leave Constitutional?
Is U.S. Government Tactical Switch From Too Big To Fail To Too Big To Leave Constitutional? In the March 2016 issue of Life Science Leader magazine, my Editor’s Note, The U.S. Tax Man Cometh, The U.S. Corporations Leaveth, referenced the Pfizer-Allergan merger as pretty much a done deal. Little did I know then that the U.S. government would stoop to implementing government policies more familiar to those living in the former U.S.S.R., than a country founded on freedom and famous for supporting free enterprise. While not losing...  Continue Reading...
Are You Committed To Being A Better Leader?
Are You Committed To Being A Better Leader? I recently cracked open Leadership Vertigo, a book by S. Max Brown and Tanveer Naseer. I was immediately enthralled when the authors hit me with this tidbit. “Gallup research has found that the top 25 percent of teams (i.e., the best managed) versus the bottom 25 percent in any workplace (i.e., the worst managed), have nearly 50 percent fewer accidents and 41 percent fewer quality defects.”  Continue Reading...
The Best Pharma Manufacturing Conference You’ve Never Heard Of
The Best Pharma Manufacturing Conference You’ve Never Heard Of Thanks to Outsourced Pharma chief editor Louis Garguilo taking the lead on serving as host of Life Science Leader magazine’s annual CMO Leadership Awards celebration and reception in New York City, my time was suddenly freed up to explore for new educational opportunities. And while I will admit to being biased as to the quality of educational opportunities offered by our own Outsourced Pharma conferences, I recently got back from an event ...  Continue Reading...
How PhRMA Is Adapting To The Industry’s New Reality
How PhRMA Is Adapting To The Industry’s New Reality PhRMA held its 2016 annual meeting March 9 and 10 in Washington, D.C. This was the first annual meeting held under the new leadership regime of Stephen Ubl. Having spent more than 10 years as the president and CEO of the Advanced Medical Technology Association (AdvaMed), Ubl took the PhRMA helm just three days after former Turing Pharmaceutical CEO Martin Shkreli made national headlines with his drug-price increase antics.  Continue Reading...
R&D Leadership Summit Provides Ear-Opening Experience
R&D Leadership Summit Provides Ear-Opening Experience Life Science Leader magazine and CNBC were the only two members of the media invited to attend the 6th Annual R&D Leadership (RDL) Summit (I will explain why this is significant in a moment). Produced by the Conference Forum with support from PRA Health Sciences, the event provides an extremely intimate opportunity for R&D executives to network and openly discuss some of the biopharmaceutical industry’s most controversial issues (e.  Continue Reading...
What Will Be The End Result Of Bullying Biopharma?
What Will Be The End Result Of Bullying Biopharma? If as adults we could invisibly walk on school playgrounds during recess, we might hear the stock response recited when encountering a bully — ‘Sticks and stones may break my bones, but words will never hurt me.”  Continue Reading...
BIO CEO 2016 Educational Sessions Provide Enlightenment
BIO CEO 2016 Educational Sessions Provide Enlightenment During this year’s BIO CEO Conference (partially covered here), much of my time was spent in the educational sessions, which I would rank as some of the best I have seen at any conference — ever. For example ...  Continue Reading...
Is Attending BIO CEO A Waste Of Your Time?
Is Attending BIO CEO A Waste Of Your Time? Sometimes it is worthwhile to stop and consider the value of your time, not from a financial perspective, but rather how much you’ve used and how much you have left. If you did, you might be much more discriminating in where you would choose to spend it. Consider this: the average U.S. male’s life expectancy is 76. This means that in less than 14,600 hours my time fuel tank will be exactly one-third full, or depending on your...  Continue Reading...